Tirzepatide dosage: the full titration schedule explained

Last updated 2026-07-27

What is the standard tirzepatide dosage schedule?

The FDA-approved titration for both Zepbound (weight management) and Mounjaro (type 2 diabetes) starts everyone at the same place: 2.5mg injected under the skin once a week, for the first 4 weeks. That starting dose isn't meant to do much therapeutically. It's there to let your gut adjust before the real dose-finding begins ^[1]. After week 4, the dose steps up by 2.5mg increments every 4 weeks, as tolerated, until you reach an effective maintenance dose or the 15mg ceiling. The full ladder looks like this: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg. Each rung is a 4-week minimum stay before moving up, according to the Zepbound prescribing information ^[1]. | Week | Dose | Purpose |

How fast should you increase the tirzepatide dose?

Every 4 weeks is the standard interval, not a suggestion you can freely compress. The clinical trials that generated the safety data (SURMOUNT-1 through 4, SURPASS-1 through 5) all used 4-week steps, and the FDA label mirrors that exactly ^[1][3]. Moving faster wasn't tested and isn't advised. Moving slower is common and, honestly, often smart. If nausea or GI upset shows up at a new dose, staying at that level for an extra 4 weeks (or even going back down a step) before trying again is a normal, label-supported move. The prescribing information notes that if a dose isn't tolerated, providers should consider delaying escalation ^[1]. There's no data showing that patience costs you long-term results. What slows people down is quitting altogether because the side effects hit hard in week one of a jump. A slower ramp usually beats a fast one that ends in discontinuation.

What is the maximum tirzepatide dose?

15mg once weekly is the ceiling for both Zepbound and Mounjaro. There's no approved dose above that, and no clinical trial has tested higher for either indication ^[1][3]. In SURMOUNT-1, the 15mg group had the largest average weight loss: 20.9% of body weight at 72 weeks by one estimand, compared to 15% on 5mg and about 19.5% on 10mg ^[2]. In SURPASS-2, the 15mg dose produced an average HbA1c reduction of 2.30 percentage points at 40 weeks in people with type 2 diabetes, versus 2.01 points with semaglutide 1mg ^[4]. More isn't automatically better for every individual. Some people get strong results at 5mg or 7.5mg and reasonably stay there, especially if GI side effects become an issue higher up. The dose that works is the one you can sustain, not necessarily the top of the range.

How does tirzepatide dosage differ for weight loss versus type 2 diabetes?

The titration ladder is identical: 2.5mg start, 2.5mg increases every 4 weeks, 15mg max. What differs is the brand name and the FDA-reviewed indication. Zepbound is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition ^[1]. Mounjaro is approved for type 2 diabetes glycemic control ^[3]. Some prescribers use Mounjaro off-label for weight loss, since it's the same molecule, same doses, same manufacturer (Eli Lilly). Insurance coverage and prior authorization requirements typically hinge on the diagnosis code tied to whichever brand is prescribed, not the dose itself. Compounded tirzepatide, sourced through telehealth platforms and compounding pharmacies, usually follows the same numeric ladder because that's the only published human dosing data that exists. But compounded product isn't FDA-approved, isn't tested for the same manufacturing standards, and the FDA has issued warnings about counterfeit and substandard versions of compounded semaglutide and tirzepatide circulating through some channels ^[5].

What if a dose is too strong or side effects are severe?

Staying at the current dose, or dropping back one step, is the standard move. Nausea, vomiting, diarrhea, constipation, and stomach pain are the most common tirzepatide side effects, reported in roughly 12-26% of trial participants depending on the specific symptom and dose ^[1][2]. These usually cluster around dose increases and fade within days to a couple of weeks. If vomiting or diarrhea is severe enough to cause dehydration, that's a reason to contact a provider, not push through alone. Tirzepatide's label carries warnings about acute pancreatitis (signs include severe, persistent abdominal pain, sometimes radiating to the back) and gallbladder disease, including gallstones and cholecystitis ^[1][3]. Rapid weight loss itself raises gallstone risk independent of the drug mechanism. The boxed warning on both Zepbound and Mounjaro concerns thyroid C-cell tumors, based on findings in rodent studies. Tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) ^[1][3]. It is not known whether tirzepatide causes MTC in humans; no cases have been confirmed in the clinical trial database as of the current label, but the FDA required the warning based on the animal signal and how GLP-1 class drugs behave in rodent thyroid tissue. If you're new to injecting, reviewing Tirz Rx how to inject and Tirz Rx injection sites before your first dose reduces a lot of the anxiety that makes side effects feel worse than they are.

How is tirzepatide dosed by injection, and where is it injected?

Tirzepatide is a subcutaneous injection, meaning it goes into the fat layer just under the skin, not into muscle. The FDA-approved injection sites are the abdomen, thigh, and upper arm, rotated week to week to reduce irritation at any one spot ^[1]. It's dosed once weekly, on the same day each week if possible, with or without food. The label allows a window of up to 4 days early or late if a dose is missed, without needing to skip or double up, as long as at least 3 days remain until the next scheduled dose ^[1]. If more than 4 days have passed, skip that dose and resume the normal weekly schedule. Branded pens (Zepbound, Mounjaro) come as single-dose, pre-filled devices at the exact prescribed strength, so there's no drawing up or measuring. Compounded tirzepatide, by contrast, usually arrives as a multi-dose vial of lyophilized powder that has to be reconstituted with bacteriostatic water and drawn up with an insulin syringe. That process introduces real room for dosing error if the concentration math is off. The how to reconstitute Tirz Rx guide covers the actual math step by step, since getting the mg-per-mL calculation wrong is the single most common mistake people make with compounded product.

What is the difference between compounded tirzepatide dosing and Zepbound/Mounjaro dosing?

The dosing ladder (2.5mg to 15mg, 4-week steps) is the same because that's the only human data in existence. What changes is quality assurance. Zepbound and Mounjaro are manufactured by Eli Lilly under FDA-approved manufacturing standards, with each pen tested for exact potency and sterility before it ships ^[1][3]. Compounded tirzepatide is prepared by 503A or 503B pharmacies, which operate under different oversight than commercial drug manufacturing. The FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients, and the agency has published guidance and warnings specifically about tirzepatide products being compounded improperly, including with the wrong salt form (tirzepatide salts, rather than the base compound used in the approved drugs) ^[5]. Compounding became legally common in the U.S. during the period when Mounjaro and Zepbound were on the FDA drug shortage list. Once the FDA declared the tirzepatide shortage resolved in December 2024, the legal basis for mass compounding under shortage exceptions narrowed considerably, though some compounding continues under other provisions for patients with documented medical need for a different dose or formulation ^[5]. A provider-reviewed path (checking labs, verifying contraindications like MTC/MEN2 history, confirming the pharmacy's sourcing) is the difference between a program built on trial-grade dosing logic and one built on a spreadsheet. Tirz Rx's model runs through provider review before any prescription moves to its fulfilling pharmacy partner, which matters more for compounded product than it does for a Lilly pen, precisely because the manufacturing safeguards aren't automatic.

How long does it take tirzepatide to start working at each dose?

Some appetite suppression is often noticeable within the first 1-2 weeks, even at the 2.5mg starting dose, though this dose is not considered clinically effective for weight loss on its own ^[1]. Meaningful, measurable weight loss and blood sugar improvement generally show up after reaching the 5mg dose and staying on it for several weeks. In SURMOUNT-1, average weight loss trajectories kept climbing through roughly 72 weeks without an obvious plateau at any single dose, meaning results build over months, not days ^[2]. In SURPASS trials, HbA1c reductions were often visible by 12 weeks even before full titration was complete ^[4]. Patience with the timeline matters more than patience with the side effects, in a way. The drug's terminal half-life is about 5 days, which is why steady-state blood levels take roughly 4 weeks to build after any dose change, matching the titration interval almost exactly ^[1]. For the pharmacokinetic detail behind that number, see Tirz Rx half life.

How long is a typical tirzepatide treatment course?

There's no FDA-defined endpoint or maximum duration. SURMOUNT-1 ran 72 weeks; a companion trial, SURMOUNT-4, specifically studied what happens after stopping, and the results were not reassuring for anyone hoping for a short course. Participants who stopped tirzepatide after 36 weeks and switched to placebo regained an average of 14% of the weight they'd lost by week 88, while those who stayed on the drug continued losing weight (an average of 25.3% total loss from baseline) ^[6]. That trial data supports treating tirzepatide as a long-term, chronic-disease medication rather than a bridge. Obesity and type 2 diabetes are both managed as ongoing conditions in most clinical guidance, and tirzepatide's own label doesn't specify a stop date ^[1][3]. That said, plenty of people do choose cycles, tapering off for cost, side effect, or personal reasons and restarting later. If you're considering that path, retitrating from a lower dose rather than jumping back to your last maintenance dose is the safer approach, since tolerance built up over months of use doesn't necessarily persist after stopping. More on the practical timing questions is in Tirz Rx cycle length.

Who should not take tirzepatide, regardless of dose?

A personal or family history of medullary thyroid carcinoma or MEN2 syndrome is an absolute contraindication at any dose, per both the Zepbound and Mounjaro labels ^[1][3]. A prior serious hypersensitivity reaction to tirzepatide or any component of the formulation is also disqualifying. Pregnancy is another clear line. Animal reproduction studies showed adverse fetal effects, and the label recommends discontinuing tirzepatide at least 1 month before a planned pregnancy given the drug's slow clearance ^[1]. Tirzepatide is not studied in children under 18 for weight management, and pediatric use for diabetes is limited. People with a history of pancreatitis need a careful conversation with a provider before starting, since tirzepatide trials excluded some of these patients and the drug carries pancreatitis warnings independent of prior history ^[1]. Severe gastroparesis and active gallbladder disease are similarly flagged as reasons for extra caution, not blanket exclusion in every case, but definitely a discussion before the first injection.

What dose reductions or adjustments are needed for kidney or liver problems?

Tirzepatide's label states no dose adjustment is required for renal impairment, including patients with severe kidney disease or those on dialysis, based on pharmacokinetic study data showing similar drug exposure across kidney function levels ^[1]. That's a genuinely useful feature of the drug compared to some older diabetes medications that require careful renal dosing. Similarly, no dose adjustment is specified for hepatic impairment in the current label, though tirzepatide hasn't been extensively studied in patients with severe liver disease, and clinical judgment applies there ^[1][3]. GI side effects like vomiting and diarrhea can cause dehydration, which does affect kidney function acutely, independent of any baseline kidney disease. That's the more common real-world kidney concern with this drug class, not the dosing pharmacokinetics themselves.

Frequently asked questions

What is the starting dose of tirzepatide?

2.5mg once weekly, for the first 4 weeks, for both Zepbound and Mounjaro. This dose is a tolerability starter and is not considered high enough to produce meaningful weight loss or blood sugar control on its own, according to the FDA prescribing information.

How much weight can you lose on 5mg vs 15mg tirzepatide?

In SURMOUNT-1, average weight loss at 72 weeks was about 15% of body weight on the 5mg maintenance dose and about 20.9% on 15mg. Individual results vary widely; these are trial averages, not guarantees, and depend on diet, activity, and how long someone stays on the drug.

Can you skip doses or increase faster than every 4 weeks?

No clinical trial tested faster titration, so the FDA label specifies 4-week minimum intervals between dose increases. Going slower (staying longer at a dose) is common and label-supported if side effects appear. Skipping a full week without medical guidance isn't recommended, though a 4-day grace window exists for a late dose.

Is 15mg tirzepatide the strongest available dose?

Yes. 15mg once weekly is the maximum FDA-approved dose for both Zepbound and Mounjaro. No trial has tested doses above 15mg, and no higher-strength pen or vial exists in the approved product line.

What happens if you stop tirzepatide?

SURMOUNT-4 trial data showed people who stopped tirzepatide after 36 weeks regained an average of 14% of their lost weight by week 88, while those who continued kept losing weight. This is why most clinical guidance treats tirzepatide as a long-term therapy rather than a short course.

Do compounded tirzepatide doses match Zepbound and Mounjaro doses?

Compounding pharmacies typically use the same 2.5mg to 15mg ladder because it's the only published human dosing data. But compounded product isn't FDA-reviewed for potency or sterility, and the FDA has warned about substandard and counterfeit compounded tirzepatide circulating in some channels.

Where do you inject tirzepatide?

The FDA-approved injection sites are the abdomen, thigh, and upper arm, given subcutaneously (under the skin, not into muscle). Sites should be rotated week to week to reduce skin irritation and lumps at any single spot.

What are the most common tirzepatide side effects at each dose?

Nausea, diarrhea, vomiting, constipation, and stomach pain are most common, reported in roughly 12-26% of trial participants depending on symptom and dose. These cluster around dose increases and typically improve within one to two weeks as the body adjusts.

Who should not take tirzepatide at any dose?

Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not take tirzepatide at any dose, per the boxed warning on both Zepbound and Mounjaro labels. Pregnancy and prior serious hypersensitivity reactions are also contraindications.

Does tirzepatide dosage differ between Zepbound and Mounjaro?

No. Both use the identical 2.5mg to 15mg titration schedule with 4-week steps. The difference is the FDA-approved indication (weight management for Zepbound, type 2 diabetes for Mounjaro) and which insurance codes apply, not the dosing math itself.

Do you need a lower tirzepatide dose if you have kidney disease?

No dose adjustment is required for kidney impairment, including severe kidney disease or dialysis, according to the FDA label, based on pharmacokinetic studies showing similar drug exposure regardless of kidney function. This is different from many older diabetes medications.

How long does each tirzepatide dose take to reach full effect?

Steady-state blood levels take roughly 4 weeks to build after any dose change, matching tirzepatide's approximately 5-day half-life and the standard titration interval. Visible weight loss and blood sugar improvements typically build over months rather than appearing within days.

Sources

1. FDA, Zepbound (tirzepatide) prescribing information: Dosing schedule, injection sites, missed dose window, contraindications, boxed warning, renal/hepatic dosing
2. NEJM, SURMOUNT-1 trial results (Jastreboff et al., 2022): Average weight loss percentages by dose (5mg, 10mg, 15mg) at 72 weeks
3. FDA, Mounjaro (tirzepatide) prescribing information: Diabetes indication, identical dosing ladder, boxed warning for MTC/MEN2
4. The Lancet, SURPASS-2 trial results (Frias et al., 2021): HbA1c reduction at 40 weeks comparing tirzepatide 15mg to semaglutide 1mg
5. JAMA, SURMOUNT-4 trial results (Aronne et al., 2024): Weight regain after tirzepatide discontinuation versus continuation at 88 weeks
6. ClinicalTrials.gov, SURMOUNT-1 study record: NCT number and trial design for SURMOUNT-1
7. ClinicalTrials.gov, SURPASS-2 study record: NCT number and trial design for SURPASS-2
8. ClinicalTrials.gov, SURMOUNT-4 study record: NCT number and trial design for SURMOUNT-4